Moderna started the third phase of clinical trials of potential mRNA-1273 coronavirus vaccine. The study will be conducted jointly with the National Institute of Allergy and Infectious Diseases - NIAID and with support from the U.S. Department of Health's Office of Advanced Biomedical Research and Development - BARDA.